Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Tolerability of Molecular Hydrogen in Patients With Parkinson's Disease

NCT03971617 is registered in ClinicalTrials.gov with Stony Brook University as lead sponsor.

NCT NCT03971617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03971617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Tolerability of Molecular Hydrogen in Patients With Parkinson's Disease
Lead sponsor
Stony Brook University
Phase
Phase 2/3
Overall status
Terminated
Start date
May 29, 2019
Completion date
April 29, 2021
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease